Welcome to our dedicated page for Supernus Pharma news (Ticker: SUPN), a resource for investors and traders seeking the latest updates and insights on Supernus Pharma stock.
Supernus Pharmaceuticals develops and commercializes treatments for central nervous system diseases. Company news centers on its neuroscience portfolio, including approved treatments for attention-deficit hyperactivity disorder, Parkinson's disease-related dyskinesia and hypomobility, postpartum depression, epilepsy, migraine, cervical dystonia, and chronic sialorrhea.
Recurring updates cover product revenue trends for Qelbree, GOCOVRI, ZURZUVAE, ONAPGO and other CNS therapies, quarterly financial results, collaboration and licensing revenue, investor conference participation, and pipeline activity for novel CNS product candidates such as SPN-820 in major depressive disorder.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced that Jack A. Khattar, President and CEO, will participate in a fireside chat at the Bank of America 2026 Health Care Conference on May 12, 2026 at 3:40 p.m. PT (6:40 p.m. ET) at the Encore Hotel in Las Vegas.
Investors may request meetings through the Bank of America coordinator. A live audio webcast and a 60-day archived replay will be available via the company’s Investor Relations Events & Presentations page at www.supernus.com/Investors.
Supernus (Nasdaq: SUPN) reported Q1 2026 total revenues of $207.7M, up 39% year-over-year, driven by combined growth-product revenues of $149.1M (+56%). Qelbree sales were $77.9M (+20%) and GOCOVRI $35.2M (+15%). Collaboration revenue from ZURZUVAE was $27.6M. Operating loss narrowed to $8.3M; adjusted operating earnings were $28.7M. Net loss was $2.3M (EPS $0.04). Cash and equivalents were ~$384.2M. Company reiterated full-year 2026 guidance, including total revenue target of $840–$870M and ONAPGO sales guidance of $45–$70M.
Supernus Pharmaceuticals (Nasdaq: SUPN) will report its first quarter 2026 financial and business results after market close on Tuesday, May 5, 2026. Management will host a conference call and webcast the same day at 4:30 p.m. ET with prepared remarks followed by Q&A.
The live webcast will be available in the Events & Presentations section of the company investor website and replayed for 60 days. Participants may pre-register to receive dial-in details and a personalized conference code; dial-in is recommended 15 minutes early.
Alpha Cognition (Nasdaq: ACOG) appointed Bethany Sensenig to its Board of Directors, effective April 15, 2026. Ms. Sensenig brings decades of finance, strategy, and operations experience, including CFO roles at Radius Health and 9 Meters, and Biogen P&L responsibility for >$1 billion across 30 countries. The company said her expertise will support the commercial launch of ZUNVEYL and ongoing development of its sublingual program. Alpha Cognition also announced that founding director Len Mertz will not seek re-election after guiding the company to an FDA-approved product.
Supernus (Nasdaq: SUPN) reported record fourth-quarter total revenues of $211.6M (+21% YoY) and full-year 2025 revenues of $719.0M (+9% YoY). Combined growth-product revenues were $161.3M Q4 (+45% YoY) and $521.8M FY (+40% YoY).
The company completed the Sage acquisition, received FDA approval and launched ONAPGO (Q4 net sales $8.9M) and provided 2026 guidance of $840M–$870M total revenues with adjusted operating earnings of $140M–$170M. Cash and marketable securities were $308.7M at year-end.
Supernus Pharmaceuticals (Nasdaq: SUPN) said management will participate in three March 2026 investor conferences: TD Cowen (March 2), Jefferies Biotech on the Beach (March 10), and Barclays Global Healthcare (March 11).
Webcasts: TD Cowen and Barclays sessions will be webcast and archived for 60 days on the company website; investors should contact conference coordinators to arrange meetings.
Supernus Pharmaceuticals (Nasdaq: SUPN) will report fourth quarter and full year 2025 financial and business results after market close on February 24, 2026. Management will host a conference call and webcast the same day at 4:30 p.m. ET.
The event will include prepared remarks, a Q&A session, and a live webcast available on the company Investor Relations website; a replay will be accessible for 60 days following the call.
Lunai Bioworks (NASDAQ:LNAI) says its Augusta AI platform is now commercial after 12 months of development and is in active negotiations with pharmaceutical and drug‑discovery partners. The company highlights three revenue engines: AI drug discovery (CNS and new oncology pilot), AI biodefense programs targeting government contracts, and an allogeneic dendritic cell immunotherapy with published preclinical tumor regressions and an LOI for licensing.
The release emphasizes faster target validation via high‑throughput in vivo testing, near‑term pilots that can expand to commercial relationships, and ongoing efforts to finalize biodefense funding and a pharma royalty partnership.
Biogen (SUPN) announced that Health Canada issued a Notice of Compliance for ZURZUVAE (zuranolone) on December 9, 2025, for the treatment of moderate or severe postpartum depression (PPD) in adults following childbirth.
ZURZUVAE is a once-daily, 14-day oral single-course treatment with clinical benefits seen as early as Day 3, significant reduction by Day 15, and sustained effect through Day 45. Approval was supported by the NEST program (ROBIN and SKYLARK).
Supernus Pharmaceuticals (Nasdaq: SUPN) announced that Jack A. Khattar, President and CEO, will present at the Bank of America Securities 2025 CNS Therapeutics Virtual Conference on Monday, December 8, 2025 at 3:20 p.m. ET.
Investors can request meetings through the Bank of America conference coordinator. A live audio webcast will be available via the company’s Events & Presentations page on www.supernus.com, and an archived replay will remain on the site for 60 days after the conference.